Clinical Trial Update: MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating MDX-060 in relapsed or refractory anaplastic large cell lymphoma (systemic and primary cutaneous) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Cutaneous Anaplastic Large Cell Lymphoma
• Systemic Anaplastic Large Cell Lymphoma

Drugs mentioned

• MDX-060

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Lymphoma, Large-Cell | Phase 2 | Status: WITHDRAWN